Market Share GrowthHeplisav has continued to gain and maintain market share, with an estimated share of the U.S. HBV market increasing to ~43% in Q1.
Product Approval And Market ExpansionHeplisav-B is the only two-dose adult Hepatitis B vaccine approved in the U.S., European Union, and UK.
Revenue GrowthHeplisav's Q1 sales, although seasonally soft, showed a healthy year-over-year growth of 36%.